Evidence map›Paper›PMID 32628898›Full record

ReviewUnited European gastroenterology journal2020

Metabolic endoscopy: Today's science-tomorrow's treatment.

Alia Hadefi, Marianna Arvanitakis, Vincent Huberty, Jacques Devière

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in United European gastroenterology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Endoscopy for Metabolic Diseases.Journal of clinical medicine · 2026
    Review
  2. Article
  3. Endoscopic bariatrics: Current status and emerging technologies.World journal of gastrointestinal endoscopy · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Alia HadefiDepartment of Gastroenterology, Hepatopancreatology, and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Marianna ArvanitakisDepartment of Gastroenterology, Hepatopancreatology, and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Vincent HubertyDepartment of Gastroenterology, Hepatopancreatology, and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Jacques DevièreDepartment of Gastroenterology, Hepatopancreatology, and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Université Libre de Bruxelles · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity, type 2 diabetes mellitus (T2DM) and nonalcoholic steatohepatitis are increasing pandemic metabolic disorders. Lifestyle intervention (LSI) is the cornerstone treatment for these but is successful as standard care alone in only a few patients, given the modest weight loss at mid and long term. Conversely, bariatric surgery is the only proven effective treatment for these metabolic disorders, albeit offered only in a small percentage of cases because of its invasiveness and cost. The so-called

Indexed as

Bariatric SurgeryChronic DiseaseComorbidityDiabetes Mellitus, Type 2EndoscopyEndoscopy, Digestive SystemGlobal Burden of DiseaseHumansNon-alcoholic Fatty Liver DiseaseObesityTreatment OutcomeWeight Lossendoscopic bariatric and metabolic therapymetabolic disordersnonalcoholic steatohepatitisObesitytype 2 diabetes

Identifiers

PMID32628898
PMCPMC7437083
OpenAlexW3039761253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.